Literature DB >> 11772121

Drug treatment of elderly patients with acute myocardial infarction: practical recommendations.

W S Aronow1.   

Abstract

Aspirin (acetylsalicylic acid) should be administered to patients on day 1 of an acute myocardial infarction (MI) and continued indefinitely. Early intravenous beta-blockade should be used during acute MI. beta-blockers should be continued indefinitely. Angiotensin-converting enzyme (ACE) inhibitors should be used in patients with acute MI with ST-segment elevation in two or more anterior precordial leads. ACE inhibitors should be used during and after acute MI in patients with chronic heart failure (CHF) or with a left ventricular ejection fraction < or =40%. There are no class I indications for using calcium channel antagonists during and after acute MI. Intravenous heparin should be used in patients with acute MI undergoing coronary revascularisation and in patients at high risk for systemic embolisation. Enoxaparin should be used in patients with non-Q-wave MI. Thrombolytic therapy should be considered in patients with acute MI with ST-segment elevation in contiguous leads of a 12-lead electrocardiogram or with left bundle branch block. Platelet glycoprotein IIb/IIIa inhibitors should be administered intravenously as an adjunct to heparin and aspirin in patients with non-Q-wave MI. Intravenous nitroglycerin should be used: (i) for the first 24 to 48 hours in patients with acute MI and CHF, large anterior MI, persistent ischaemia or hypertension; and (ii) continued beyond 48 hours in patients with recurrent angina pectoris or persistent pulmonary congestion. Long-acting nitrates should be given after MI, along with beta-blockers, to patients with angina pectoris. There are no class I indications for using intravenous magnesium during acute MI. The routine use of antiarrhythmic drugs other than beta-blockers during and after acute MI is not recommended.

Entities:  

Mesh:

Year:  2001        PMID: 11772121     DOI: 10.2165/00002512-200118110-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  68 in total

1.  Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction.

Authors:  K A Bybee; R S Wright; B A Williams; J G Murphy; D R Holmes; S L Kopecky
Journal:  Am J Cardiol       Date:  2001-03-15       Impact factor: 2.778

2.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

3.  Effect of propranolol on circadian variation of ventricular arrhythmias in elderly patients with heart disease and complex ventricular arrhythmias.

Authors:  W S Aronow; C Ahn; A D Mercando; S Epstein
Journal:  Am J Cardiol       Date:  1995-03-01       Impact factor: 2.778

4.  Effect of propranolol after acute myocardial infarction in patients with congestive heart failure.

Authors:  K Chadda; S Goldstein; R Byington; J D Curb
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

Review 5.  Postinfarction use of beta-blockers in elderly patients.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

6.  Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group.

Authors:  T Gundersen; A M Abrahamsen; J Kjekshus; P K Rønnevik
Journal:  Circulation       Date:  1982-12       Impact factor: 29.690

7.  Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients > or = 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction > or = 40%.

Authors:  W S Aronow; C Ahn; A D Mercando; S Epstein; I Kronzon
Journal:  Am J Cardiol       Date:  1994-08-01       Impact factor: 2.778

8.  Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction.

Authors:  L K Hine; N Laird; P Hewitt; T C Chalmers
Journal:  Arch Intern Med       Date:  1989-12

9.  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.

Authors: 
Journal:  JAMA       Date:  1982-03-26       Impact factor: 56.272

10.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321

View more
  4 in total

Review 1.  Aspirin for the prevention of cardiovascular events in the elderly.

Authors:  Isabelle Mahé; Alain Leizorovicz; Charles Caulin; Jean-François Bergmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

2.  Running in polluted air is a two-edged sword - physical exercise in low air pollution areas is cardioprotective but detrimental for the heart in high air pollution areas.

Authors:  Thomas Münzel; Omar Hahad; Andreas Daiber
Journal:  Eur Heart J       Date:  2021-07-01       Impact factor: 29.983

3.  Cigarette Smoking Is Related to Endothelial Dysfunction of Resistance, but Not Conduit Arteries in the General Population-Results From the Gutenberg Health Study.

Authors:  Omar Hahad; Natalie Arnold; Jürgen H Prochaska; Marina Panova-Noeva; Andreas Schulz; Karl J Lackner; Norbert Pfeiffer; Irene Schmidtmann; Matthias Michal; Manfred Beutel; Philipp S Wild; John F Keaney; Andreas Daiber; Thomas Münzel
Journal:  Front Cardiovasc Med       Date:  2021-05-19

4.  Reduction of environmental pollutants for prevention of cardiovascular disease: it's time to act.

Authors:  Thomas Münzel; Mark R Miller; Mette Sørensen; Jos Lelieveld; Andreas Daiber; Sanjay Rajagopalan
Journal:  Eur Heart J       Date:  2020-11-01       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.